Personal tools

Beendete Studien

MDS: MEDI D4190C00007

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents.Read More

CML: BMS 180373

A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination of Dasatinib (BMS-354825) plus Nivolumab (BMS-936558) in Patients with Chronic Myeloid Leukemia (CML)Read More


Phase I/II pilot trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in patients with relapsed or refractory acute myeloid leukemia (AML) and no intensive treatment is possible.Read More

AML: Bayer 16520

An open-label Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY 1143572 given in a once-daily or an intermittent dosing schedule in subjects with advanced acute leukemia.Read More

MDS: BI 1230.33

An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Patients With Previously Untreated High-risk Myelodysplastic Syndrome (MDS) or ...Read More

Diverse: Biotest 989

A Randomized, Double-blind, Parallel-arm, Phase I Study to Evaluate the Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab (MabThera) Induction Immunotherapy as a First-line Treatment in Patients With Low Tumor Burden Follicular LymphomaRead More

SIADH: Otsuka156-12-203

A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone SecretionRead More

AML: Astellas 2215-CL-0101

Phase I/II pilot trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in patients with relapsed or refractory acute myeloid leukemia (AML) and no intensive treatment is possible.Read More

AML: AbbVie M14-358

A Phase 1b Study of ABT-199 in Combination with Azacytidine or Decitabine in Treatment Naive Subjects with AML who are >=65 years of age and who are not eligible for Standard induction therapyRead More

CCC: PCI Biotech A202/12

A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of AmphinexTMinduced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/Cisplatin Chemotherapy in Patients with Advanced Inoperable CholangiocarcinomasA Phase I/II Dose ...Read More

CLL: I.R.I.S CL1-55746-001

Phase I dose-escalation study of oral administration of the selective Bcl2 inhibitor S 55746 in patients with refractory or relapsed Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma.Read More

Diverse: EMR 100070-001

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications.Read More

HCC: EMR 200095-005

A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver Function Who Have Failed Sorafenib TreatmentRead More

MM: Abbvie M14-467

Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects with Relapsed and Refractory Multiple MyelomaRead More

MM: Celgene Medi4736-MM-001

A phase 1b multicenter, open-Label study to determine the recommended dose and of Durvalumab (MEDI4736) either as Monotherapy or in combination with Pomalidomide (POM) with or without lowdose Dexamethasone (DEX) in subjects with Relapsed and refractory Multiple Myeloma (RRMM).Read More

MM: Celgene Medi4736-MM-003

A Phase 3, multicenter, open-label, study to determine the safety and efficacy for the combination of Durvalumab and Daratumumab in subjects with relapsed and refractory multiple myeloma.Read More

AML: Catapult D-00272-CT2014002

This is a Phase I/II trial to determine safety, clinical efficacy and feasibility of a gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).Read More

Diverse: Novartis CINC280A2108

A multicenter, open label, phase 1 dose escalation study to evaluate the pharmacokinetics, safety, and tolerability of INC280 tablet formulation with food in patients with cMET dysregulated advanced solid tumors.Read More

Diverse: Rigontec RGT 100

A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors.Read More

Diverse: BMS CA 209-9GW

Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid TumorsRead More